Page 4 - Ingo Mellinghoff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Summary Neuro-oncologist Ingo Mellinghoff first became intrigued by scientific questions regarding brain tumors while working in the lab of physician-scientist Charles Sawyers before both came to MSK. Now, Dr. Mellinghoff leads MSK’s Department of Neurology as it deploys innovative technologies to understand how these cancers develop and progress. When neuro-oncologist Ingo Mellinghoff was named Chair of Memorial Sloan Kettering’s Department of Neurology in October 2020, it marked the culmination of a career devoted to studying how cancer affects the brain. Dr. Mellinghoff previously ser...

ASX RELEASE 7 January 2021 GBM AGILE PIVOTAL STUDY COMMENCES RECRUITMENT TO PAXALISIB ARM Sydney, 7 January 2021 -... | January 27, 2021

Posted on 288 Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) — The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia’s paxalisib and Kintara’s VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for regis...